scholarly journals Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity

2014 ◽  
Vol 14 (12) ◽  
pp. 1825-1836 ◽  
Author(s):  
Rik J Lories ◽  
Kurt de Vlam
Keyword(s):  
Clinical Practice ◽  
Psoriatic Arthritis ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Tumour Necrosis Factor Inhibitors ◽  
Necrosis Factor

scholarly journals Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors

2012 ◽  
Vol 72 (7) ◽  
pp. 1176-1181 ◽  
Author(s):  
Stephanie Finzel ◽  
Sebastian Kraus ◽  
Sarah Schmidt ◽  
Axel Hueber ◽  
Juergen Rech ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Treatment Strategies ◽  
Appendicular Skeleton ◽  
Micro Ct ◽  
Treatment Groups ◽  
Tumour Necrosis Factor Inhibitors ◽  
Necrosis Factor

ObjectivesTo investigate whether methotrexate or tumour necrosis factor inhibitors (TNFi) affect osteophyte formation in patients with psoriatic arthritis (PsA).Methods41 patients with PsA were examined for the presence of osteophytes and erosions at the metacarpophalangeal joints by high-resolution micro-CT imaging. The size of each individual lesion was quantified at baseline and 1-year follow-up in PsA patients treated with TNFi (N=28) or methotrexate (N=13). Groups were comparable for age, sex, disease duration and activity and baseline burden of osteophytes.ResultsIn total, 415 osteophytes (TNFi N=284, methotrexate N=131) were detected. Osteophyte size increased significantly from baseline to follow-up in the TNFi group (mean±SEM change +0.23±0.02 mm; p<0.0001) and the methotrexate group (+0.27±0.03 mm, p<0.0001). In both treatment groups, the majority of osteophytes showed progression (TNFi 54.3%, methotrexate 61.1%), whereas regression of lesions was rare (less than 10%). In contrast to osteophytes, clinical disease activity decreased in both groups of PsA patients and erosions showed an arrest of progression in both groups.ConclusionsOsteophytes progress in PsA patients treated with either methotrexate or TNFi. These data provide the first evidence that pathological bone formation in the appendicular skeleton of patients with PsA is not affected by current antirheumatic treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document